Novel Preoperative Immune Prognostic Index for Predicting Outcomes in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

Overview

Journal In Vivo

Specialty Oncology

Date 2025 Feb 26

PMID 40010955

Authors

Ken Shibata

Kosuke Iwatani

Y U Imai

Kentaro Yoshihara

Keiichiro Miyajima

Wataru Fukuokaya

Kagenori Ito

Taro Igarashi

Takafumi Yanagisawa

Kojiro Tashiro

Shusuke Tsuzuki

Steffi Kar Kei Yuen

Jeremy Yuen-Chun Teoh

Brendan A Yanada

Yusuke Koike

Tatsuya Shimomura

Hiroki Yamada

Akira Furuta

Jun Miki

Takahiro Kimura

Fumihiko Urabe

Affiliations

Soon will be listed here.

Abstract

Background/aim: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with the level of lactate dehydrogenase, predicts outcomes in various cancers. Its utility as a preoperative biomarker in upper tract urothelial carcinoma (UTUC) patients remains unexplored.

Patients And Methods: This is a retrospective study of UTUC patients who underwent radical nephroureterectomy. Patients were stratified into favorable, intermediate, and poor LIPI groups. Non-urothelial tract recurrence-free survival (NUTRFS) was evaluated using Kaplan-Meier analysis, and Cox regression analyses were performed to identify risk factors for NUTRFS.

Results: A total of 567 UTUC patients were included, with 46.4% in the favorable, 44.6% in the intermediate, and 9.0% in the poor (9.0%) LIPI groups. The median participant age was 74 years, with a median follow-up of 26 months. Kaplan-Meier curves demonstrated that NUTRFS was significantly worse in patients with poor and intermediate LIPI scores than in those with favorable LIPI scores. Furthermore, combining LIPI status with pathological stages (pT3-4/ypT2-4) and lymph node metastasis status improved postoperative non-urothelial tract recurrence prognosis assessment.

Conclusion: The preoperative LIPI is a prognostic indicator for patients with UTUC undergoing nephroureterectomy. Its predictive accuracy improves when combined with advanced pathological stages and lymph node metastasis status.

References

Margulis V, Shariat S, Matin S, Kamat A, Zigeuner R, Kikuchi E . Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115(6):1224-33. DOI: 10.1002/cncr.24135. View

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi A . Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018; 6(1):74. PMC: 6048712. DOI: 10.1186/s40425-018-0383-1. View

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

Munoz J, Ellison L . Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000; 164(5):1523-5. View

Obayashi K, Miki J, Fukuokaya W, Yanagisawa T, Kimura S, Tsuzuki S . The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy. Int J Clin Oncol. 2021; 27(2):396-402. DOI: 10.1007/s10147-021-02059-8. View

Grob G, Rogers D, Pandolfo S, Vourganti S, Buscarini M, Mehrazin R . Oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma: a literature review. Transl Androl Urol. 2023; 12(8):1351-1362. PMC: 10481200. DOI: 10.21037/tau-22-882. View

Liu H, Yang X, Yang X, Dong Z, Chen Z, Hong J . The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:691002. PMC: 8496897. DOI: 10.3389/fonc.2021.691002. View

Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee R . Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol. 2012; 19(13):4337-44. PMC: 3576920. DOI: 10.1245/s10434-012-2499-8. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

10.

Tan P, Chen J, Xie N, Xu H, Ai J, Xu H . Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma?. Cancer Med. 2018; 7(10):5096-5106. PMC: 6198201. DOI: 10.1002/cam4.1751. View

11.

Heng D, Xie W, Regan M, Harshman L, Bjarnason G, Vaishampayan U . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2):141-8. PMC: 4144042. DOI: 10.1016/S1470-2045(12)70559-4. View

12.

Motzer R, Bacik J, Murphy B, Russo P, Mazumdar M . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1):289-96. DOI: 10.1200/JCO.2002.20.1.289. View

13.

Uribe-Querol E, Rosales C . Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2016; 2015:983698. PMC: 4706937. DOI: 10.1155/2015/983698. View

14.

Mbeutcha A, Roupret M, Kamat A, Karakiewicz P, Lawrentschuk N, Novara G . Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2016; 35(3):337-353. DOI: 10.1007/s00345-016-1826-2. View

15.

Redrow G, Matin S . Upper tract urothelial carcinoma: epidemiology, high risk populations and detection. Minerva Urol Nefrol. 2016; 68(4):350-8. View

16.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

17.

Ruiz-Banobre J, Areses-Manrique M, Mosquera-Martinez J, Cortegoso A, Afonso-Afonso F, de Dios-Alvarez N . Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2020; 8(6):1078-1085. PMC: 6976357. DOI: 10.21037/tlcr.2019.11.07. View

18.

Wu M, Lin P, Xu L, Yu Z, Chen Q, Gu H . Prognostic Role of Serum Lactate Dehydrogenase in Patients With Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol. 2020; 10:677. PMC: 7252225. DOI: 10.3389/fonc.2020.00677. View

19.

Meyers D, Stukalin I, Vallerand I, Lewinson R, Suo A, Dean M . The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2019; 11(11). PMC: 6896022. DOI: 10.3390/cancers11111713. View

20.

McMillan D, Crozier J, Canna K, Angerson W, McArdle C . Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22(8):881-6. DOI: 10.1007/s00384-006-0259-6. View